Table 1.

Preclinical studies of BH3 mimetics in combination with different agents against PC cells eliciting additive or synergistic cytotoxicity.

BH3 mimetic	Target	Combination with	Reference
Pan-BH3 mimetics
(-)-Gossypol	Bcl-2, Bcl-xl, Bcl-w, Mcl-1	Docetaxel	Meng et al., 2008
(-)-Gossypol	Bcl-2, Bcl-xl, Bcl-w, Mcl-1	Sorafenib	Lian et al., 2012
(-)-Gossypol	Bcl-2, Bcl-xl, Bcl-w, Mcl-1	Valproic acid	Ouyang et al., 2011
(-)-Gossypol	Bcl-2, Bcl-xl, Bcl-w, Mcl-1	Radiation	Xu et al., 2005
GX15-070	Bcl-2, Bcl-xl, Bcl-w, Mcl-1	Bicalutamide	Santer et al., 2015
BI-97CI	Bcl-2, Bcl-xl, Bcl-w, Mcl-1	mda-7/IL-24	Dash et al., 2011
Specific BH3 mimetics
ABT-263	Bcl-2, Bcl-xl, Bcl-w	Paclitaxel	Wang et al., 2015
ABT-737	Bcl-2, Bcl-xl, Bcl-w	Docetaxel	Parrondo et al., 2013
ABT-263/737	Bcl-2, Bcl-xl, Bcl-w	Docetaxel	Tamaki et al., 2014
ABT-737	Bcl-2, Bcl-xl, Bcl-w	Cisplatin	Bray et al., 2009
ABT-263	Bcl-2, Bcl-xl, Bcl-w	MLN2238	Wei et al., 2014
ABT-263	Bcl-2, Bcl-xl, Bcl-w	CP-d/n-ATF5-S1	Karpel-Massler et al., 2016
ABT-263/737	Bcl-2, Bcl-xl, Bcl-w	2DG	Yamaguchi et al., 2011
ABT-737	Bcl-2, Bcl-xl, Bcl-w	Pim kinase inhibitor	Song and Kraft, 2012
ABT-737	Bcl-2, Bcl-xl, Bcl-w	Pseudolaric acid B (PAB)	Tong et al., 2013
ABT-737	Bcl-2, Bcl-xl, Bcl-w	Transcriptional inhibitor ARC	Pandit and Gartel, 2010
ABT-737	Bcl-2, Bcl-xl, Bcl-w	MSeA	Yin et al., 2012
ABT-737	Bcl-2, Bcl-xl, Bcl-w	TRAIL	Song et al., 2008